Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $5.0650 (2.53%) ($5.0650 - $5.0650) on Thu. Apr. 15, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.17% (three month average) | RSI | 46 | Latest Price | $5.0650(2.53%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS advances 1.9% a day on average for past five trading days. | Weekly Trend | ADMS declines -2% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Normal for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) VCIT(90%) PCY(89%) HYG(87%) BWX(75%) TLT(74%) | Factors Impacting ADMS price | ADMS will decline at least -2.585% in a week (0% probabilities). USO(-27%) SKYY(-15%) UUP(-11%) ACES(-8%) URA(-7%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -2.585% (StdDev 5.17%) | Hourly BBV | 0.5 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-8.16(-261.11%) | 5 Day Moving Average | $4.74(6.86%) | 10 Day Moving Average | $4.81(5.3%) | 20 Day Moving Average | $4.98(1.71%) | To recent high | -23.9% | To recent low | 0.9% | Market Cap | $143m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |